$-0.69 EPS Expected for Acer Therapeutics Inc. (ACER); The Marcus (MCS) Covered By 6 Bullish Analysts Last Week

April 19, 2018 - By Richard Conner

Among 6 analysts covering Marcus Corp (NYSE:MCS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Marcus Corp had 15 analyst reports since July 24, 2015 according to SRatingsIntel. On Thursday, February 22 the stock rating was maintained by FBR Capital with “Buy”. B. Riley & Co maintained the stock with “Buy” rating in Monday, August 24 report. B. Riley & Co upgraded The Marcus Corporation (NYSE:MCS) on Friday, July 24 to “Buy” rating. The stock has “Buy” rating by Benchmark on Wednesday, October 4. The firm has “Buy” rating by FBR Capital given on Tuesday, January 30. The rating was initiated by Gabelli with “Buy” on Thursday, October 15. As per Friday, October 27, the company rating was maintained by B. Riley & Co. The firm earned “Buy” rating on Friday, July 29 by Benchmark. The firm has “Outperform” rating given on Friday, July 28 by Barrington Research. B. Riley & Co maintained The Marcus Corporation (NYSE:MCS) on Wednesday, July 19 with “Buy” rating. See The Marcus Corporation (NYSE:MCS) latest ratings:

22/02/2018 Broker: Barrington Rating: Buy
22/02/2018 Broker: FBR Capital Rating: Buy New Target: $34.0 Maintain
30/01/2018 Broker: FBR Capital Rating: Buy New Target: $34.0 Maintain
22/01/2018 Broker: FBR Capital Rating: Buy New Target: $34.0
27/10/2017 Broker: B. Riley & Co Rating: Buy New Target: $36.0 Maintain

Analysts expect Acer Therapeutics Inc. (NASDAQ:ACER) to report $-0.69 EPS on May, 11.They anticipate $0.55 EPS change or 44.35% from last quarter’s $-1.24 EPS. After having $-0.63 EPS previously, Acer Therapeutics Inc.’s analysts see 9.52% EPS growth. The stock decreased 1.00% or $0.19 during the last trading session, reaching $18.87. About 2,535 shares traded. Acer Therapeutics Inc. (NASDAQ:ACER) has risen 126.38% since April 19, 2017 and is uptrending. It has outperformed by 114.83% the S&P500.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company has market cap of $141.48 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease . It currently has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Investors sentiment decreased to 1.03 in Q4 2017. Its down 0.10, from 1.13 in 2017Q3. It worsened, as 13 investors sold The Marcus Corporation shares while 46 reduced holdings. 17 funds opened positions while 44 raised stakes. 16.61 million shares or 0.34% more from 16.55 million shares in 2017Q3 were reported. Teton Advsr Inc invested in 365,000 shares or 0.92% of the stock. Deutsche Financial Bank Ag stated it has 0% of its portfolio in The Marcus Corporation (NYSE:MCS). Kbc Grp Inc Nv holds 0% or 10,699 shares in its portfolio. Rice Hall James & Assocs Ltd Company holds 102,460 shares. State Board Of Administration Of Florida Retirement System holds 0% of its portfolio in The Marcus Corporation (NYSE:MCS) for 17,861 shares. Wells Fargo & Mn reported 30,197 shares. Wellington Mgmt Gp Llp reported 0% of its portfolio in The Marcus Corporation (NYSE:MCS). Hotchkis And Wiley Cap Mngmt reported 0% in The Marcus Corporation (NYSE:MCS). Congress Asset Mngmt Ma stated it has 44,716 shares or 0.02% of all its holdings. Mason Street Advisors Limited Liability holds 0% or 5,005 shares. Jpmorgan Chase And stated it has 89,182 shares or 0% of all its holdings. Stifel accumulated 9,363 shares. Teachers Retirement System Of The State Of Kentucky invested 0% in The Marcus Corporation (NYSE:MCS). Wedge Capital Mngmt L L P Nc reported 0.01% in The Marcus Corporation (NYSE:MCS). Rhumbline Advisers has invested 0% of its portfolio in The Marcus Corporation (NYSE:MCS).

Since March 7, 2018, it had 0 buys, and 4 sales for $1.22 million activity. Another trade for 12,750 shares valued at $393,410 was made by GERSHOWITZ DIANE M on Friday, April 6. $229,616 worth of stock was sold by KISSINGER THOMAS F on Friday, March 16. Shares for $306,254 were sold by MILSTEIN PHILIP L.

The Marcus Corporation (NYSE:MCS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts